

BENCHMARKS
Nifty 18,338.55 176.8

NSE GAINER-LARGE CAP
IRCTC 5,463.55 534.75

FEATURED FUNDS ★★★★★
ICICI Prudential Midcap ... 17.64% INVEST NOW

MARKET WATCH ▼

THE ECONOMIC TIMES | Industry

English Edition | E-Paper

Subscribe Sign In

Special Offer on ET Prime

Home ETPRime Markets News **Industry** RISE Politics Wealth MF Tech Jobs Opinion NRI Panache ET NOW More ▼

Auto ▼ Banking/Finance ▼ Cons. Products ▼ Energy ▼ Renewables ▼ Ind'l Goods/Svs ▼ **Healthcare/Biotech** ▼ Services ▼ Media/Entertainment ▼ More ▼

Business News › Industry › Healthcare/Biotech › Pharmaceuticals › Reliance Life Sciences appeals marketing restrictions on breast cancer drug

Reliance Life Sciences appeals marketing restrictions on breast cancer drug

Synopsis


The counsel is appealing conditions including the restrictions placed on the labelling of TrastuRel as well as those placed on using Roche's data.



NEW DELHI: After **Biocon and Mylan**, **Reliance Life Sciences** has approached the **Delhi High Court** to appeal against an earlier order that imposed marketing restrictions to its copy of Swiss biotech giant **Roche's breast cancer drug**, Herclon (trastuzumab).

After Reliance was prevented from launching its product, **TrastuRel**, in November, an April 25 court judgement finally allowed the company to introduce its product along with restrictions similar to the ones imposed on Biocon's CANMAb and Mylan's Hertraz.

The judgement, given by Justice **Manmohan Singh**, directed that Reliance could manufacture, market and advertise TrastuRel without calling it a “bio similar” or in any way ascribing biosimilarity to inventor, Roche's products—Herceptin, Herclon and Biceltis.



Popular in Industry

1. Ratan Tata credits Chandra for decision behind Air India buy




2. Vodafone, Aditya Birla Group may invest \$400 million into Vodafone Idea





SECTIONS Reliance Life Sciences appeals marketing restrictions on breast cancer drug



Recommended by

The company's appeal will be heard along with **Biocon** NSE -1.31% and Mylan's by Justices Badar Durrez Ahmed and Sanjeev Sachdeva on July 21, 2016. The judges have called on Roche's subsidiary, Genentech, for a response in the meantime.

Reliance's appeal is distinct from Biocon and Mylan's, argued Reliance Life Sciences counsel **Pratibha Singh** at court on June 3. Reliance was given an injunction before it had launched TrastuRel, whereas CANMAb and Hertraz were already in the market when Roche sued them, she told judges.

The counsel is appealing conditions including restrictions placed on TrastuRel labelling as well as those on using Roche's data, according to Singh.

The April 25 judgement stated that Reliance could also manufacture and market the drug by qualifying the International Non-proprietary Name (INN)

3. Govt asks power plants to blend 10% imported coal to step up supply



4. Five banks may bid for Citi's



SHARE FONT SIZE SAVE PRINT COMMENT

5. Tata Sons shortlists candidates for Air India CEO post



TOP TRENDING INDUSTRY TERMS



- Tata Power
- Vodafone Idea
- Ratan Tata
- Bharat Biotech

Most Popular News

1. 4th richest Indian shrugs off ESG rules to own one-third in a cigarette firm



NEXT STORY

Bharat Bio hopes to soon submit trial data for intranasal vaccine

(Catch all the **Business News**, **Breaking News**, **Events** and **Latest News** Updates)

By Teena Thacker, ET Bureau Last Updated: Oct 14, 2021, 07:15 AM IST

SHARE FONT SIZE SAVE PRINT COMMENT

Download **THE ECONOMIC TIMES NEWS APP** to get Daily Market Updates & Live

Synopsis


"The trials are ongoing, and we expect to submit data by the end of this year," a company insider said. The trials, including over 600 participants, are being conducted by dividing the volunteers into three groups.

ADD COMMENT

After receiving positive recommendations from the expert committee on **Covaxin** use for COVID-19, **Biotech** is now looking to submit the trial results of its COVID-19 **vaccine** by end of this year, people in the know told ET.

BACK TO TOP

"The trials are ongoing, and we expect to submit data by the end of this year," a



company insider said. The trials, including over 600 participants, are being conducted by dividing the volunteers into three groups.

The first group is administered Covaxin as the first dose and intranasal vaccine as the second dose. The second group will get both doses in the form of intranasal vaccine.

post-pandemic digital playbook
7 mins read
cyclical investment strategy from the past
14 mins read

Subscribe to ETPrime



The third group will get the intranasal vaccine as the first dose and Covaxin jab as the second dose. The doses are given 28 days apart. The intranasal vaccine can be game changer in the vaccination drive because it offers the convenience of administration.

The drug regulatory authority had in August given its approval to Hyderabad-based Bharat Biotech to conduct phase-2/3 trials on its intranasal vaccine.

The adenoviral intranasal vaccine BBV154 is the first of its kind Covid-19 jab which has been undergoing human trials in India. The phase-1 trial in healthy volunteers of age groups ranging from 18 to 60 years was well tolerated, the ministry of science and technology said in a statement earlier.

It also said the vaccine was found to be safe, immunogenic and well-tolerated in the preclinical toxicity studies and was able to elicit high levels of neutralizing antibodies in animal studies.

The development of Bharat Biotech's intranasal vaccine has been supported by the department of biotechnology (DBT) and Biotechnology Industry Research Assistance Council (BIRAC). The company strategised to fast-track research and development efforts, especially for vaccine development, diagnostics, drug repurposing, therapeutics and testing.

Bharat Biotech's clinical trials demonstrated 77.8% efficacy against symptomatic Covid-19 against severe illness during the phase-3 clinical trials.

READ MORE NEWS ON

Popular in Industry

- 1. Ratan Tata credits Chandra for decision behind Air India buy
- 2. Vodafone, Aditya Birla Group may invest \$400 million into Vodafone Idea
- 3. Govt asks power plants to blend 10% imported coal to

Most Popular Opinion

- 1. Growth is gathering momentum, but...
- 4. Five banks may bid for Citi's
- 2. India consumer businesses GatiShakti: Breaking silos in
- 3. Growth history: Sifting through puzzles
- 5. Tata Sons shortlists candidates for Air India CEO

Top Category Deals

UPTO 70% OFF

UPTO 40% OFF



TOP TRENDING INDUSTRY TERMS

Spicejet India Railways Punit Goenka IMF

Most Popular News

- 1. 4th richest Indian shrugs off ESG rules to own one-third in a cigarette firm
- 2. Rakesh Jhunjhunwala's latest pick is a three-bagger of last one year
- 3. Is Bitcoin headed towards record high? Explained in 4 charts
- 4. One of India's biggest technology recruiters is giving the campus a skip

(Catch all the **Business News**, **Breaking News** Events and **Latest News** Updates on **The Economic Times**.)

Download **The Economic Times News App** to get Daily Market Updates & Live Business News.

ETPrime stories of the day



OMNICHANNEL

Jewellery on rent to virtual shopping: decoding Titan's post-pandemic digital playbook

7 mins read



INVESTING

Realty boom, capex cycle, Unitech's fall: what pro-cyclical investors can learn from the past

14 mins read



LOGISTICS

Why Rivigo, which hired from all sectors, is zeroing in on seasoned logistics hands for its revival

11 mins read

Subscribe to **ETPrime**

Most Popular Opinion

1. Growth is gathering momentum, but...
2. GatiShakti: Breaking silos in logistics
3. Growth history: Sifting through puzzles

Top Category Deals



Instant 10% discount
Kitchen & Dining



200+ Deals
Major Appliances

[Explore 20+ Categories >](#)

Latest News

1. Drug case live: No bail for Aryan Khan today, order reserved for October 20
2. Eye on Pakistan, Amit Shah recalls 2016 surgical strikes
3. Lakhimpur key points: SIT takes Union minister's son, 3 others to recreate sequence of events

Search News, Stock Quotes & NAV

BROWSE COMPANIES:

- (A) (B) (C) (D) (E) (F) (G) (H) (I) (J) (K) (L) (M) (N) (O) (P) (Q) (R) (S) (T) (U) (V) (W) (X) (Y) (Z)
- (1) (2) (3) (4) (5) (6) (7) (8) (9)

[BACK TO TOP](#)

Trending Now

India Railways	Zee Entertainment
Vodafone Idea	Air India
Bharat Biotech	Petrol Price
CIL	Jiopages
IRCTC News	Railways ministry
Indian Navy News	Netflix News
Ministry of Corporate Affairs	Delhi Metro
Reliance Jio	

Hot On Web

Aryan Khan Drug Case LIVE Updates	Sensex today
Cryptocurrency	Mutual funds SIP 2021
What are multi asset funds	What are balanced mutual funds
Global markets	Mutual funds
Breaking news	LTC Cash Voucher Scheme
SGX Nifty	Sensex Live
IRCTC share price	Infosys share price
Rupee	Aadhaar Card
How to save Income Tax	

ET Verticals

Auto News	Retail News
Health News	Telecom News
Energy News	IT News
Real Estate News	Marketing & Advertising News
Technology News	CFO News
IT Security News	

Other Useful Links

About Us	Subscribe to ET Prime
Book your Newspaper Subscription	Create Your Own Ad
Advertise with Us	Terms of Use & Grievance Redressal
Privacy policy	Contact Us
RSS	DNPA Code of Ethics

Popular Categories

Auto	Banking/Finance
Cons. Products	Energy
Renewables	Ind'l Goods/Svs
Healthcare/Biotech	Services
Media/Entertainment	Transportation
Tech	Telecom
Miscellaneous	CSR
Environment	

In Case You Missed It

India Railways	Punit Goenka
IMF	CIL
Vodafone Idea	Air India
Bharat Biotech	Petrol Price Today
Jiopages	AGR dues
Auto News	Banking News
Jio Fiber	

More From Our Network

Pune Mirror	Bangalore Mirror	Ahmedabad Mirror
ItsMyAscent	Education Times	Brand Capital
Mumbai Mirror	Times Now	Indiatimes
महाराष्ट्र टाइम्स	ವಿಜಯ ಕರ್ನಾಟಕ	Go Green
AdAge India	Eisamay	IGN India
IamGujarat	Times of India	Samayam Tamil
Samayam Telugu	Miss Kyra	Bombay Times
Filmipop	MX Player	Newspaper Subscription
Times Prime	Colombia	NBT Gold Podcast
Ei Samay Gold Podcast	MX ShareKaro App	MX TakaTak App

Services

Longwalks App

Follow Us On:

Download ET App:

SUBSCRIBE TO
OUR
NEWSLETTER

Copyright © 2021 Bennett, Coleman & Co. Ltd. All rights reserved. For reprint rights: [Times Syndication Service](#)

BACK TO TOP